Vascular Aging and Lp299v Study

Vascular Aging Clinical Trial

Official title:

Impact of Lp299v on Vascular Aging in Healthy Adults

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05296395
• Other study ID #: PRO43157
• Status: Recruiting
• Phase: N/A
• Start date: February 1, 2023
• Est. completion date: September 22, 2027

Study information

• Verified date: March 2024
• Source: Medical College of Wisconsin
• Contact: Michael E Widlansky, MD
• Phone: 414-955-6759
• Email: mwidlans[@]mcw.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Emerging data suggest the gut microbiota regulates multiple mechanisms related to vascular aging, but no intervention targeting the gut microbiota has been tested in older adults without cardiovascular risk factors or cardiovascular disease. Early human data suggest an increase in potentially pathological gut metabolites such as trimethylamine-N-oxide (TMAO) are associated with older age, increased vascular stiffness, increased oxidative stress, and reduced nitric oxide (NO) bioavailability as evidenced by impaired endothelium-dependent vasodilation. Based on this data, the investigators hypothesize that supplementation with Lp299v will reverse human vascular aging in healthy older adults free of known traditional cardiovascular risk factors.

Description:

Multiple lines of evidence suggest that aging results in significant changes in the composition and metabolism of the gut microbiota that accelerate mechanisms responsible for vascular aging. Recent work established cross-sectional associations between phenotypically older vasculature (with increased vascular stiffness and impaired brachial endothelium-dependent vasodilation) and age-related alterations on the composition of the gut microbiota and metabolites that are derived from microbial metabolism such as TMAO (trimethylamine-N-oxide), nicotinamide, tryptophan, and purines. Animal data also suggests short-chain fatty acids favorably impact endothelium-dependent vasodilation. SCFAs exert a direct anti-inflammatory effect on mononuclear cells and increase glucagon-like protein 1 (GLP-1) production which activates endothelial nitric oxide synthase (eNOS) and increases NO levels. Taken together, these data suggest aging-related changes in the gut microbiota could adversely affect vascular health through multiple mechanisms, even in the absence of concomitant cardiovascular risk factors. Six weeks of Lp299v supplementation in 36 otherwise healthy smokers reduced systemic inflammation, as evidenced by reductions in leptin (an adipokine that stimulates IL-6 production) and IL-6 levels, reduced monocyte adhesion to endothelial cells, and reduced circulating fibrinogen levels (elevated in the setting of inflammation). In addition, Lp299v supplementation reduced oxidative stress based on reduced urinary F2-isoprostanes and had a modest lowering effect on systolic blood pressure. The investigators will recruit 20 healthy older adults (10 men, 10 women ages 50 or older) without traditional cardiac risk factors or prevalent cardiovascular disease and randomize subjects into a 6-week, double-blind, randomized, placebo-controlled clinical trial of Lp299v supplementation. Measurements of micro-and macrovascular function, systemic inflammation, and stool microbiota composition will be made.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: September 22, 2027
• Est. primary completion date: September 22, 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years to 99 Years

Eligibility

Inclusion Criteria:

• Ages 50-99 years
• For women: 12 months or more since last menstruation

Exclusion Criteria:

• Systolic Blood Pressure = 130 mmHg or Diastolic BP = 80mmHg
• Currently taking pharmacological therapies for hypertension, dyslipidemia, or glucose control
• Diabetes (type 1 or 2) or glycosylated hemoglobin = 5/7%
• LDL Cholesterol > 160 mg/dL or Total Cholesterol > 200 mg/dL
• Cigarette use within 3 years of enrollment
• Average of > 7500 steps per day as measured during screening period
• Received probiotics, prebiotics, and/or antibiotics within six weeks of enrollment
• History of chronic renal insufficiency, liver dysfunction, or cancer besides non-melanoma skin carcinomas or localized prostate cancer requiring systemic treatment within 3 years of enrollment
• History of inflammatory rheumatic diseases known to increase atherosclerotic cardiovascular risk (e.g. rheumatoid arthritis, systemic lupus erythematosus)
• Known history of cognitive impairment or inability to follow study procedures
• GI tract illnesses such as short gut syndrome, inflammatory bowel disease, or an ileostomy
• Daily alcohol use

Related Conditions & MeSH terms

• Vascular Aging

Intervention

Other:
• Lactobacillus Plantarum 299v in fermented oat drink
The intervention is a probiotic lactobacillus that is contained in food products in the US
• Heat-Killed Placebo control fermented drink
The intervention is the GoodBelly StraightShort that has been treated to heat kill all Lp299v

Locations

Country	Name	City	State
United States	Medical College of Wisconsin	Milwaukee	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
Medical College of Wisconsin

Country where clinical trial is conducted

United States, 

References & Publications (22)

Brandsma E, Kloosterhuis NJ, Koster M, Dekker DC, Gijbels MJJ, van der Velden S, Rios-Morales M, van Faassen MJR, Loreti MG, de Bruin A, Fu J, Kuipers F, Bakker BM, Westerterp M, de Winther MPJ, Hofker MH, van de Sluis B, Koonen DPY. A Proinflammatory Gut Microbiota Increases Systemic Inflammation and Accelerates Atherosclerosis. Circ Res. 2019 Jan 4;124(1):94-100. doi: 10.1161/CIRCRESAHA.118.313234. — View Citation

Brunt VE, Gioscia-Ryan RA, Casso AG, VanDongen NS, Ziemba BP, Sapinsley ZJ, Richey JJ, Zigler MC, Neilson AP, Davy KP, Seals DR. Trimethylamine-N-Oxide Promotes Age-Related Vascular Oxidative Stress and Endothelial Dysfunction in Mice and Healthy Humans. Hypertension. 2020 Jul;76(1):101-112. doi: 10.1161/HYPERTENSIONAHA.120.14759. Epub 2020 Jun 10. — View Citation

Brunt VE, Gioscia-Ryan RA, Richey JJ, Zigler MC, Cuevas LM, Gonzalez A, Vazquez-Baeza Y, Battson ML, Smithson AT, Gilley AD, Ackermann G, Neilson AP, Weir T, Davy KP, Knight R, Seals DR. Suppression of the gut microbiome ameliorates age-related arterial dysfunction and oxidative stress in mice. J Physiol. 2019 May;597(9):2361-2378. doi: 10.1113/JP277336. Epub 2019 Feb 27. — View Citation

Chai W, Dong Z, Wang N, Wang W, Tao L, Cao W, Liu Z. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes. 2012 Apr;61(4):888-96. doi: 10.2337/db11-1073. Epub 2012 Feb 22. — View Citation

Claesson MJ, Cusack S, O'Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, Marchesi JR, Falush D, Dinan T, Fitzgerald G, Stanton C, van Sinderen D, O'Connor M, Harnedy N, O'Connor K, Henry C, O'Mahony D, Fitzgerald AP, Shanahan F, Twomey C, Hill C, Ross RP, O'Toole PW. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1(Suppl 1):4586-91. doi: 10.1073/pnas.1000097107. Epub 2010 Jun 22. — View Citation

Ding L, Zhang J. Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol Sin. 2012 Jan;33(1):75-81. doi: 10.1038/aps.2011.149. Epub 2011 Nov 28. — View Citation

Geva-Zatorsky N, Sefik E, Kua L, Pasman L, Tan TG, Ortiz-Lopez A, Yanortsang TB, Yang L, Jupp R, Mathis D, Benoist C, Kasper DL. Mining the Human Gut Microbiota for Immunomodulatory Organisms. Cell. 2017 Feb 23;168(5):928-943.e11. doi: 10.1016/j.cell.2017.01.022. Epub 2017 Feb 16. — View Citation

Hebuterne X. Gut changes attributed to ageing: effects on intestinal microflora. Curr Opin Clin Nutr Metab Care. 2003 Jan;6(1):49-54. doi: 10.1097/00075197-200301000-00008. — View Citation

Ke Y, Li D, Zhao M, Liu C, Liu J, Zeng A, Shi X, Cheng S, Pan B, Zheng L, Hong H. Gut flora-dependent metabolite Trimethylamine-N-oxide accelerates endothelial cell senescence and vascular aging through oxidative stress. Free Radic Biol Med. 2018 Feb 20;116:88-100. doi: 10.1016/j.freeradbiomed.2018.01.007. Epub 2018 Jan 8. Erratum In: Free Radic Biol Med. 2018 Dec;129:608-610. — View Citation

Li T, Chen Y, Gua C, Li X. Elevated Circulating Trimethylamine N-Oxide Levels Contribute to Endothelial Dysfunction in Aged Rats through Vascular Inflammation and Oxidative Stress. Front Physiol. 2017 May 30;8:350. doi: 10.3389/fphys.2017.00350. eCollection 2017. — View Citation

Menni C, Lin C, Cecelja M, Mangino M, Matey-Hernandez ML, Keehn L, Mohney RP, Steves CJ, Spector TD, Kuo CF, Chowienczyk P, Valdes AM. Gut microbial diversity is associated with lower arterial stiffness in women. Eur Heart J. 2018 Jul 1;39(25):2390-2397. doi: 10.1093/eurheartj/ehy226. — View Citation

Naruszewicz M, Johansson ML, Zapolska-Downar D, Bukowska H. Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers. Am J Clin Nutr. 2002 Dec;76(6):1249-55. doi: 10.1093/ajcn/76.6.1249. — View Citation

Natarajan N, Hori D, Flavahan S, Steppan J, Flavahan NA, Berkowitz DE, Pluznick JL. Microbial short chain fatty acid metabolites lower blood pressure via endothelial G protein-coupled receptor 41. Physiol Genomics. 2016 Nov 1;48(11):826-834. doi: 10.1152/physiolgenomics.00089.2016. Epub 2016 Sep 23. — View Citation

Schirmer M, Smeekens SP, Vlamakis H, Jaeger M, Oosting M, Franzosa EA, Horst RT, Jansen T, Jacobs L, Bonder MJ, Kurilshikov A, Fu J, Joosten LAB, Zhernakova A, Huttenhower C, Wijmenga C, Netea MG, Xavier RJ. Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity. Cell. 2016 Dec 15;167(7):1897. doi: 10.1016/j.cell.2016.11.046. No abstract available. — View Citation

Schirmer M, Smeekens SP, Vlamakis H, Jaeger M, Oosting M, Franzosa EA, Ter Horst R, Jansen T, Jacobs L, Bonder MJ, Kurilshikov A, Fu J, Joosten LAB, Zhernakova A, Huttenhower C, Wijmenga C, Netea MG, Xavier RJ. Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity. Cell. 2016 Nov 3;167(4):1125-1136.e8. doi: 10.1016/j.cell.2016.10.020. Erratum In: Cell. 2016 Dec 15;167(7):1897. Cell. 2016 Dec 15;167(7):1897. — View Citation

Sharma R, Padwad Y. Probiotic bacteria as modulators of cellular senescence: emerging concepts and opportunities. Gut Microbes. 2020 May 3;11(3):335-349. doi: 10.1080/19490976.2019.1697148. Epub 2019 Dec 10. — View Citation

Tang CH, Lu DY, Yang RS, Tsai HY, Kao MC, Fu WM, Chen YF. Leptin-induced IL-6 production is mediated by leptin receptor, insulin receptor substrate-1, phosphatidylinositol 3-kinase, Akt, NF-kappaB, and p300 pathway in microglia. J Immunol. 2007 Jul 15;179(2):1292-302. doi: 10.4049/jimmunol.179.2.1292. — View Citation

Tazawa R, Uchida K, Fujimaki H, Miyagi M, Inoue G, Sekiguchi H, Murata K, Takata K, Kawakubo A, Takaso M. Elevated leptin levels induce inflammation through IL-6 in skeletal muscle of aged female rats. BMC Musculoskelet Disord. 2019 May 10;20(1):199. doi: 10.1186/s12891-019-2581-5. — View Citation

Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, Cameron J, Grosse J, Reimann F, Gribble FM. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012 Feb;61(2):364-71. doi: 10.2337/db11-1019. Epub 2011 Dec 21. — View Citation

Tsiotra PC, Boutati E, Dimitriadis G, Raptis SA. High insulin and leptin increase resistin and inflammatory cytokine production from human mononuclear cells. Biomed Res Int. 2013;2013:487081. doi: 10.1155/2013/487081. Epub 2012 Dec 24. — View Citation

Wu CS, Muthyala SDV, Klemashevich C, Ufondu AU, Menon R, Chen Z, Devaraj S, Jayaraman A, Sun Y. Age-dependent remodeling of gut microbiome and host serum metabolome in mice. Aging (Albany NY). 2021 Feb 17;13(5):6330-6345. doi: 10.18632/aging.202525. Epub 2021 Feb 17. — View Citation

Yang WH, Liu SC, Tsai CH, Fong YC, Wang SJ, Chang YS, Tang CH. Leptin induces IL-6 expression through OBRl receptor signaling pathway in human synovial fibroblasts. PLoS One. 2013 Sep 27;8(9):e75551. doi: 10.1371/journal.pone.0075551. eCollection 2013. — View Citation

* Note: There are 22 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Brachial Artery Flow Mediated Dilation (FMD%	This is a measurement of endothelial function in the brachial artery	6 weeks
Secondary	Nitroglycerin-Mediated Vasodilation of the brachial artery (NMD)	Measurement of vascular smooth muscle reactivity	6 weeks
Secondary	Hyperemic Flow Velocity	Measurement of microvascular endothelial function	6 weeks
Secondary	Carotid-Femoral Pulse Wave Velocity (cfPWV)	Measurement of vascular stiffness	6 weeks
Secondary	Stool microbiota alpha diversity	Diversity of bacterial species in the individual microbiome	6 weeks
Secondary	Stool microbiota beta diversity	Differences in bacterial composition between intervention arms	6 weeks
Secondary	Brachial Artery Resting Diameter	resting diameter of the brachial artery - representative of resting vascular tone	6 weeks